Literature DB >> 21315485

The effect of hypoxia and cycloxygenase inhibitors on nasal polyp derived fibroblasts.

Smadar Cohen1, Alon Nissim Ben Efraim, Francesca Levi-Schaffer, Ron Eliashar.   

Abstract

BACKGROUND AND
PURPOSE: The pathogenesis of chronic rhinosinusitis with nasal polyposis is unknown. Chronic inflammation along with local tissue hypoxia may effect polyp's growth. Activation of Cycloxygenases may also be involved. COX-2 up-regulates in response to different stimuli including hypoxia. Its activation is associated with enhanced cell proliferation. Histologically, besides inflammatory cells, increased stromal fibrosis is seen in nasal polyposis. The aims of this study were to test whether hypoxia amplifies nasal polyp fibroblasts proliferation, whether treatment with various COX inhibitors could influence fibroblasts, and whether this effect may be modulated in response to different oxygenation conditions.
MATERIALS AND METHODS: Polyp fibroblasts were incubated under hypoxic or normoxic conditions with or without NSAIDs at different concentrations for 12 or 24 hours. Cell proliferation was quantified using BrdU ELISA. Metabolic activity was evaluated using MTT assay. Cell death was measured using Annexin V staining and FACS scan.
RESULTS: No significant difference was found between proliferation of fibroblasts treated under hypoxia or normoxia. Cells incubated with indomethacin proliferated in a slightly enhanced manner compared with non-treated cells. Celecoxib inhibited fibroblast proliferation (P < .001) but did not influence cell survival. Metabolic activity of cells treated with celecoxib was significantly reduced (P < .003), unlike cells treated with indomethacin or rofecoxib.
CONCLUSION: Hypoxia does not affect fibroblasts proliferation. It may contribute to nasal polyposis pathogenesis in other ways. The anti-proliferative effect of celecoxib may be associated with cell cycle arrest rather than with pro-apoptotic activity. Celecoxib may be considered for treating nasal polyposis.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21315485     DOI: 10.1016/j.amjoto.2010.11.010

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  6 in total

1.  Vascular endothelial growth factor-D mediates fibrogenic response in myofibroblasts.

Authors:  Tieqiang Zhao; Wenyuan Zhao; Weixin Meng; Chang Liu; Yuanjian Chen; Syamal K Bhattacharya; Yao Sun
Journal:  Mol Cell Biochem       Date:  2016-01-02       Impact factor: 3.396

2.  Platelet-derived growth factor-D promotes fibrogenesis of cardiac fibroblasts.

Authors:  Tieqiang Zhao; Wenyuan Zhao; Yuanjian Chen; Victoria S Li; Weixin Meng; Yao Sun
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-12       Impact factor: 4.733

3.  Joint contracture is reduced by intra-articular implantation of rosiglitazone-loaded hydrogels in a rabbit model of arthrofibrosis.

Authors:  Diren Arsoy; Christopher G Salib; William H Trousdale; Meagan E Tibbo; Afton K Limberg; Anthony Viste; Eric A Lewallen; Nicolas Reina; Michael J Yaszemski; Daniel J Berry; Andre J van Wijnen; Mark E Morrey; Joaquin Sanchez-Sotelo; Matthew P Abdel
Journal:  J Orthop Res       Date:  2018-07-13       Impact factor: 3.494

4.  Vascular endothelial growth factor-C: its unrevealed role in fibrogenesis.

Authors:  Tieqiang Zhao; Wenyuan Zhao; Weixin Meng; Chang Liu; Yuanjian Chen; Yao Sun
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-01-24       Impact factor: 4.733

5.  Differential Regulatory Role of Soluble Klothos on Cardiac Fibrogenesis in Hypertension.

Authors:  Xue Liu; Yuanjian Chen; Cody W McCoy; Tieqiang Zhao; Darryl L Quarles; Min Pi; Syamal K Bhattacharya; Gwendalyn King; Yao Sun
Journal:  Am J Hypertens       Date:  2016-08-19       Impact factor: 2.689

6.  Roles Played by the PI3K/Akt/HIF-1α Pathway and IL-17A in the Chinese Subtype of Chronic Sinusitis with Nasal Polyps.

Authors:  Ke-Jia Cheng; Min-Li Zhou; Yong-Cai Liu; Shui-Hong Zhou
Journal:  Mediators Inflamm       Date:  2022-01-15       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.